Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec:180:103851.
doi: 10.1016/j.critrevonc.2022.103851. Epub 2022 Oct 17.

Advanced and recurrent endometrial cancer: State of the art and future perspectives

Francesca Tronconi  1 , Camilla Nero  2 , Elena Giudice  3 , Vanda Salutari  2 , Lucia Musacchio  2 , Caterina Ricci  2 , Maria Vittoria Carbone  2 , Viola Ghizzoni  2 , Maria Teresa Perri  3 , Floriana Camarda  4 , Marica Gentile  5 , Rossana Berardi  6 , Giovanni Scambia  7 , Domenica Lorusso  8
Affiliations
Review

Advanced and recurrent endometrial cancer: State of the art and future perspectives

Francesca Tronconi et al. Crit Rev Oncol Hematol. 2022 Dec.

Abstract

Patients with primary metastatic/recurrent endometrial cancer have poor prognosis and available therapeutic options are limited. Current treatment is mainly based on platinum-based chemotherapy. Recently, the Food and Drug Administration (FDA) granted approval for the combination of pembrolizumab and lenvatinib for endometrial cancer patients without microsatellite instability (MSS) progressing on a previous line of therapy while European Medicines Agency (EMA) approved the combination for all comers patients failing previous platinum treatment. Anti programmed cell death protein-1 (PD-1) dostarlimab (TSR-042) was approved as monotherapy in patients with advanced, microsatellite instable (MSI) endometrial cancer progressing to platinum treatment. Phase II-III clinical trials in metastatic endometrial cancer are mainly focused on target therapies and immunotherapy as single agents or in combination. Unfortunately, most of these trials are lacking of predictive biomarkers of response to select patients most or at least likely to benefit from those treatments.

Keywords: Chemotherapy; Hormonal therapy; Immunotherapy; Metastatic endometrial cancer; Radiation treatment; Target therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest VS reports grants from Clovis Oncology, grants from TESARO, grants from GSK, grants from Astra Zeneca, grants from MSD, grants from PHARMAMAR, grants from EISAI, grants from ROCHE, outside the submitted work; RB reports personal fees from Astra Zeneca, Boehringer Ingelheim, Novartis, MSD, Otsuka, Eli‐Lilly, Roche outside the submitted work; GS reports personal fees from ROCHE, personal fees from Clovis Oncology, personal fees from Astra Zeneca, personal fees from PharmaMar, personal fees from Tesaro, outside the submitted work; DL reports grants from ROCHE, grants and personal fees from GSK, grants and personal fees from Clovis Oncology, grants and personal fees from MSD, grants from Incyte, grants and personal fees from PHARMAMAR, grants from IMMUNOGEN, grants and personal fees from GENMAB, personal fees from AMGEN, grants and personal fees from ASTRA ZENECA, outside the submitted work; FT, CN, EG, LM, CR, MVC, VG, MTP, FC, MG have nothing to disclose.

MeSH terms

LinkOut - more resources